Document Detail

Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers.
MedLine Citation:
PMID:  11675958     Owner:  NLM     Status:  MEDLINE    
To compare the effects of an alpha, beta blocker, arotinolol, in the treatment of essential hypertension between patients with a dipper and those with a non-dipper profile by means of 24-h ambulatory blood pressure monitoring (ABPM), a multicenter single blind parallel trial was carried out in five clinical centers. After a one-week single blind placebo run-in period, the patients underwent ABPM if their clinic diastolic blood pressure (DBP) ranged from 90-109 mmHg and their clinic systolic blood pressure (SBP) was <180 mmHg. They were divided into two groups according to the absence (non-dipper group, 24 cases) or presence (dipper group, 23 cases) of nocturnal BP reduction > or =10% of daytime BP. ABPM was measured again at the end of the active treatment phase. All patients were given Arotinolol 10-20 mg twice daily for 4 weeks. Twenty four-hour systolic and diastolic average BPs (MSBP, MDBP), 24-h systolic and diastolic blood pressure load (LS BP, LDBP), daytime systolic and diastolic average BPs (dMSBP, dMDBP), daytime systolic and diastolic blood pressure load (dLSBP, dLDBP), nighttime systolic and diastolic average BPs (nMSBP, nMDBP) and nighttime systolic and diastolic blood pressure load (nLSBP, nLDBP) were calculated. Arotinolol was effective in 78.2% of dippers and 54.2% of non-dippers, but the difference in effectiveness between these groups was not statistically significant. After treatment, SBP and DBP-including 24-h, daytime and nighttime systolic and diastolic BPs- were significantly reduced in both groups. During the daytime period, the systolic and diastolic blood pressures were significantly reduced in both dippers and non-dippers, while nighttime systolic and diastolic blood pressures were significantly reduced only in the non-dipper group. No significant changes were found in the dipper group over this period. In conclusion, Arotinolol, which can be dosed twice daily, is an effective antihypertensive agent which effectively lowers blood pressure during the day while reducing nighttime blood pressure more in non-dippers than in dippers, without excessive lowering blood pressure in the latter.
H Wu; Y Zhang; J Huang; Y Zhang; G Liu; N Sun; Z Yu; Y Zhou
Related Documents :
15311148 - Home-based self-measurement of blood pressure: a proposal using new reference values (t...
25332288 - Hypertension in the united states 1999-2012: progress toward healthy people 2020 goals.
3415788 - Higher blood pressures of urban migrants from an african low-blood pressure population ...
25339298 - Pathogenesis of obstructive sleep apnoea in hypertensive patients: role of fluid retent...
9137228 - Relation of hemodynamic volume load to arterial and cardiac size.
1267538 - Haemodynamic effects of adenosine-5'-carboxylic acid-amide in the anaesthetized dog dur...
Publication Detail:
Type:  Clinical Trial; Controlled Clinical Trial; Journal Article; Multicenter Study    
Journal Detail:
Title:  Hypertension research : official journal of the Japanese Society of Hypertension     Volume:  24     ISSN:  0916-9636     ISO Abbreviation:  Hypertens. Res.     Publication Date:  2001 Sep 
Date Detail:
Created Date:  2001-10-24     Completed Date:  2002-03-22     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  9307690     Medline TA:  Hypertens Res     Country:  Japan    
Other Details:
Languages:  eng     Pagination:  605-10     Citation Subset:  IM    
Division of Hypertension, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adrenergic beta-Antagonists / administration & dosage*
Blood Pressure / drug effects
Blood Pressure Monitoring, Ambulatory
Circadian Rhythm
Hypertension / drug therapy*,  physiopathology
Middle Aged
Propanolamines / administration & dosage*
Single-Blind Method
Reg. No./Substance:
0/Adrenergic beta-Antagonists; 0/Propanolamines; 52560-77-7/arotinolol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Variations in cardiac diastolic function in hypertensive patients with different left ventricular ge...
Next Document:  Kidney cancer. Report of 170 cases